Literature DB >> 26078565

Nonalcoholic fatty liver disease, spleen and psoriasis: New aspects of low-grade chronic inflammation.

Nicola Balato1, Maddalena Napolitano1, Fabio Ayala1, Cataldo Patruno1, Matteo Megna1, Giovanni Tarantino1.   

Abstract

AIM: To investigate spleen status in psoriasis and its relationship with hepatic steatosis, Psoriasis Area and Severity Index, and insulin resistance.
METHODS: Seventy-nine psoriatic patients who were not suffering from any chronic inflammatory disease were retrospectively selected for inclusion in this study, and their complete medical records were accessed. An age- and sex-matched group of 80 non-psoriatic, obese patients was included as a control. The following relevant data were collected: age, sex, weight, height, body mass index, waist circumference, blood pressure, insulin resistance status, age at psoriasis onset, and severity of psoriasis. Abdominal ultrasonography was performed to determine spleen longitudinal diameter (SLD), and hepatic steatosis grade.
RESULTS: The SLD of control obese patients was greater than that of psoriatic subjects (P = 0.013), but body mass index predicted the size of the spleen in psoriatic patients (P < 0.001). The SLD of psoriatic patients with normal weight was significantly reduced with respect to the overweight/obese psoriatic patients (P = 0.002). A multiple regression analysis revealed that body mass index was a unique predictor of the spleen size (P < 0.001). Finally, the disease duration predicted the spleen size in psoriatic subjects (P = 0.038).
CONCLUSION: This study shows a correlation between the SLD and the duration of psoriasis.

Entities:  

Keywords:  Hepatic steatosis; Inflammation; Nonalcoholic fatty liver disease; Psoriasis; Spleen size

Mesh:

Year:  2015        PMID: 26078565      PMCID: PMC4462729          DOI: 10.3748/wjg.v21.i22.6892

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.

Authors:  K Asadullah; W Sterry; K Stephanek; D Jasulaitis; M Leupold; H Audring; H D Volk; W D Döcke
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

2.  Psoriasis and osteoporosis: data from a Southern Italian population.

Authors:  N Balato; A Balato; L Gallo; M Napolitano; C Patruno; F Ayala
Journal:  Arch Osteoporos       Date:  2012       Impact factor: 2.617

Review 3.  Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions.

Authors:  Batya B Davidovici; Naveed Sattar; Jörg C Prinz; Prinz C Jörg; Luis Puig; Paul Emery; Jonathan N Barker; Peter van de Kerkhof; Mona Ståhle; Frank O Nestle; Giampiero Girolomoni; James G Krueger
Journal:  J Invest Dermatol       Date:  2010-05-06       Impact factor: 8.551

4.  Decreased splenic mRNA expression levels of TNF-alpha and IL-6 in diet-induced obese animals.

Authors:  O Lamas; J A Martínez; A Marti
Journal:  J Physiol Biochem       Date:  2004-12       Impact factor: 4.158

5.  Chronic inflammation in psoriasis and obesity: implications for therapy.

Authors:  E A Hamminga; A J van der Lely; H A M Neumann; H B Thio
Journal:  Med Hypotheses       Date:  2006-06-15       Impact factor: 1.538

6.  IL-33 is regulated by TNF-α in normal and psoriatic skin.

Authors:  Anna Balato; Roberta Di Caprio; Luigi Canta; Martina Mattii; Serena Lembo; Annunziata Raimondo; Maria Schiattarella; Nicola Balato; Fabio Ayala
Journal:  Arch Dermatol Res       Date:  2014-02-13       Impact factor: 3.017

7.  Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors.

Authors:  Iben Marie Miller; Christina Ellervik; Shiva Yazdanyar; Gregor B E Jemec
Journal:  J Am Acad Dermatol       Date:  2013-12       Impact factor: 11.527

Review 8.  Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis.

Authors:  E A Dowlatshahi; E A M van der Voort; L R Arends; T Nijsten
Journal:  Br J Dermatol       Date:  2013-08       Impact factor: 9.302

Review 9.  Interleukin-10 and related cytokines and receptors.

Authors:  Sidney Pestka; Christopher D Krause; Devanand Sarkar; Mark R Walter; Yufang Shi; Paul B Fisher
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

Review 10.  Pathogenic mechanisms shared between psoriasis and cardiovascular disease.

Authors:  Ramin Ghazizadeh; Hajime Shimizu; Mamiko Tosa; Mohammad Ghazizadeh
Journal:  Int J Med Sci       Date:  2010-08-19       Impact factor: 3.738

View more
  8 in total

1.  Changes in metabolic parameters in psoriatic patients treated with secukinumab.

Authors:  Hsuan Ning Wang; Yu Huei Huang
Journal:  Ther Adv Chronic Dis       Date:  2020-08-03       Impact factor: 5.091

2.  Bioelectrical phase angle and psoriasis: a novel association with psoriasis severity, quality of life and metabolic syndrome.

Authors:  Luigi Barrea; Paolo Emidio Macchia; Carolina Di Somma; Maddalena Napolitano; Anna Balato; Andrea Falco; Maria Cristina Savanelli; Nicola Balato; Annamaria Colao; Silvia Savastano
Journal:  J Transl Med       Date:  2016-05-10       Impact factor: 5.531

3.  Effects of splenectomy on skin inflammation and psoriasis-like phenotype of imiquimod-treated mice.

Authors:  Hiroyo Shinno-Hashimoto; Akifumi Eguchi; Akemi Sakamoto; Xiayun Wan; Yaeko Hashimoto; Yuko Fujita; Chisato Mori; Masahiko Hatano; Hiroyuki Matsue; Kenji Hashimoto
Journal:  Sci Rep       Date:  2022-08-30       Impact factor: 4.996

4.  Prevalence of antigliadin IgA antibodies in psoriasis vulgaris and response of seropositive patients to a gluten-free diet.

Authors:  Nikolai A Kolchak; Maria K Tetarnikova; Maria S Theodoropoulou; Alexandra P Michalopoulou; Demetrios S Theodoropoulos
Journal:  J Multidiscip Healthc       Date:  2017-12-27

Review 5.  Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy.

Authors:  Giovanni Tarantino; Vincenzo Citro; Domenico Capone
Journal:  J Clin Med       Date:  2019-12-19       Impact factor: 4.241

6.  Preparation of Calcipotriol Emulsion Using Bacterial Exopolysaccharides as Emulsifier for Percutaneous Treatment of Psoriasis Vulgaris.

Authors:  Bo Song; Ruiteng Song; Min Cheng; Hairong Chu; Fang Yan; Yuzhen Wang
Journal:  Int J Mol Sci       Date:  2019-12-20       Impact factor: 5.923

7.  Is There a Link between Basal Metabolic Rate, Spleen Volume and Hepatic Growth Factor Levels in Patients with Obesity-Related NAFLD?

Authors:  Giovanni Tarantino; Vincenzo Citro; Paolo Conforti; Clara Balsano; Domenico Capone
Journal:  J Clin Med       Date:  2019-09-20       Impact factor: 4.241

8.  Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5-15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials.

Authors:  Lars Iversen; Merle Kurvits; Anja Marieke Snel-Prentø; Alan Menter
Journal:  Dermatol Ther (Heidelb)       Date:  2020-08-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.